Ruder Finn has signed a three-year contract with Japanese pharmaceutical giant Daiichi Sankyo with an annual budget set at $2.5M.
Earlier this month, DS reshuffled its U.S. management ranks. President/CEO John Gargiulo, a 17-year veteran, exited his post. Glenn Gormley, who was in charge of global R&D, took the helm.
Gargiulo also had headed the commercial division of DS. Greg Barrett, VP-marketing, was upped to that slot.
RF’s fees/expenses are divided among DS’ Tokyo headquarters and U.S. (Parsippany, N.J.) and Europe (Munich) regional offices.
Susan Goldstein, RF’s managing director/global health and wellness is the global lead on the DS work.
Elyse Margolis, senior VP, is U.S. lead, while Katy Compton-Bishop, senior VP, and Mai Tran, executive VP, head the effort in Europe and Japan, respectively.
Richard Salem is executive director-PA for DS in Jersey.